BRPI0512421A - recombinantes de avipox expressando genes do vìrus da doença febre aftosa - Google Patents

recombinantes de avipox expressando genes do vìrus da doença febre aftosa

Info

Publication number
BRPI0512421A
BRPI0512421A BRPI0512421-2A BRPI0512421A BRPI0512421A BR PI0512421 A BRPI0512421 A BR PI0512421A BR PI0512421 A BRPI0512421 A BR PI0512421A BR PI0512421 A BRPI0512421 A BR PI0512421A
Authority
BR
Brazil
Prior art keywords
disease virus
mouth disease
avipox
recombinants expressing
fmdv
Prior art date
Application number
BRPI0512421-2A
Other languages
English (en)
Inventor
Robert Nordgren
Sheena May Loosmore
Jean-Christophe Franc Audonnet
Marvin J Grubman
Original Assignee
Merial Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Ltd filed Critical Merial Ltd
Publication of BRPI0512421A publication Critical patent/BRPI0512421A/pt
Publication of BRPI0512421B1 publication Critical patent/BRPI0512421B1/pt
Publication of BRPI0512421B8 publication Critical patent/BRPI0512421B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/135—Foot- and mouth-disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

RECOMBINANTES DE AVIPOX EXPRESSANDO GENES DO VìRUS DA DOENçA FEBRE AFTOSA. A presente invenção refere-se a vetores poxvirais modificados e a métodos de fabricação e uso dos mesmos. Em particular, a invenção refe-re-se a avipox recombinante que expressa produtos de gene do vírus da doença febre aftosa (FMDV) e a composições ou vacinas que elicitam resposta imune direcionada aos produtos de gene de FMDV e que podem conferir imunidade protetora contra infecção por FMDV.
BRPI0512421A 2004-06-25 2005-04-20 Recombinantes de avipox expressando genes do vírus da doença febre aftosa BRPI0512421B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56378604P 2004-06-25 2004-06-25
US60/563,786 2004-06-25
US2006073431 2006-07-13

Publications (3)

Publication Number Publication Date
BRPI0512421A true BRPI0512421A (pt) 2008-03-04
BRPI0512421B1 BRPI0512421B1 (pt) 2014-09-09
BRPI0512421B8 BRPI0512421B8 (pt) 2022-06-28

Family

ID=36648298

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0512421A BRPI0512421B8 (pt) 2004-06-25 2005-04-20 Recombinantes de avipox expressando genes do vírus da doença febre aftosa

Country Status (9)

Country Link
US (2) US7527960B2 (pt)
EP (1) EP1773387B1 (pt)
BR (1) BRPI0512421B8 (pt)
CA (1) CA2571560C (pt)
DK (1) DK1773387T3 (pt)
EC (1) ECSP077196A (pt)
ES (1) ES2424847T3 (pt)
PL (1) PL1773387T3 (pt)
WO (1) WO2006073431A2 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9109014B2 (en) * 2009-11-02 2015-08-18 The Trustees Of The University Of Pennsylvania Foot and mouth disease virus (FMDV) consensus proteins, coding sequences therefor and vaccines made therefrom
ES2617743T3 (es) 2010-03-12 2017-06-19 Merial, Inc. Vacunas recombinantes del virus de la lengua azul y sus utilizaciones
CN101948510B (zh) * 2010-09-10 2012-08-29 中国人民解放军第二军医大学 一种o型口蹄疫病毒vp2抗原表位的分子模拟肽及其用途
EP3466443B1 (en) 2012-02-14 2020-12-16 Boehringer Ingelheim Animal Health USA Inc. Recombinant poxviral vectors expressing both rabies and ox40 proteins, and vaccines made therefrom
EP2644702A1 (en) † 2012-03-30 2013-10-02 Ceva Sante Animale Multivalent recombinant avian herpes virus and vaccine for immunizing avian species
US9828414B2 (en) * 2012-10-28 2017-11-28 Bavarian Nordic A/S Pr13.5 promoter for robust T-cell and antibody responses
KR20210088754A (ko) * 2013-03-15 2021-07-14 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 구제역 바이러스 (fmdv) 공통 단백질, 그에 대한 코딩 서열 및 그로부터 제조된 백신
CN103710384A (zh) * 2013-12-18 2014-04-09 广东华南联合疫苗开发院有限公司 小核糖核酸病毒科重组载体和病毒样颗粒及制备方法和用途
CN103740758B (zh) * 2013-12-18 2015-03-18 广东华南联合疫苗开发院有限公司 一种重组杆状病毒载体及病毒样颗粒及制备方法和用途
MX388708B (es) * 2014-09-23 2025-03-20 Boehringer Ingelheim Animal Health Usa Inc Vacunas recombinantes contra fmdv y sus usos.
CN104892734B (zh) * 2015-04-30 2019-09-13 中国科学院过程工程研究所 疏水作用层析提纯口蹄疫灭活病毒抗原的方法
CN107709554A (zh) * 2015-06-15 2018-02-16 巴法里安诺迪克有限公司 重组经修饰痘苗病毒安卡拉(mva)口蹄疫病毒(fmdv)疫苗
MA42640B1 (fr) 2015-11-23 2021-06-30 Merial Inc Protéines de fusion de dmdv et e2 et leurs utilisations
TWI760322B (zh) 2016-01-29 2022-04-11 美商百靈佳殷格翰動物保健美國有限公司 重組腺病毒載體裝載之fmdv疫苗及其用途
EA202091958A1 (ru) 2018-02-23 2021-02-04 Бёрингер Ингельхайм Ветмедика Гмбх Рекомбинантные вирусные векторные системы, экпрессирующие экзогенные гены кошачьего парамиксовируса, и вакцины, приготовленные из них
GB202217045D0 (en) * 2022-11-15 2022-12-28 Univ Cape Town Recombinant lsdv vectored foot and mouth disease antigenic constructs
CN116656731B (zh) * 2023-05-25 2024-04-12 军事科学院军事医学研究院军事兽医研究所 一种表达非洲猪瘟病毒多种蛋白的重组金丝雀痘病毒及其构建方法
CN116478939B (zh) * 2023-06-20 2023-09-08 天津瑞普生物技术股份有限公司 表达禽脑脊髓炎病毒p1和3c基因的重组禽痘病毒及其构建方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69233158T2 (de) 1991-03-07 2004-05-13 Connaught Technology Corp., Greenville Gentechnologisch hergestellter stamm für impfstoffe
US5561064A (en) 1994-02-01 1996-10-01 Vical Incorporated Production of pharmaceutical-grade plasmid DNA
CA2192342A1 (en) 1994-07-15 1996-02-01 Ann L. Lee A method for large scale plasmid purification
EP0832197A4 (en) * 1995-06-07 2002-10-16 Syntro Corp RECOMBINANT AVIAN SMALLPOX VIRUS AND USES THEREOF
MXPA02011545A (es) * 2000-05-24 2003-06-06 Merial Sas Virus del sindrome respiratorio y reproductor porcino (peesv), vacuna recombinante para el virus de la viruela.
FR2810888B1 (fr) * 2000-06-29 2004-07-30 Merial Sas Vaccin contre la fievre aphteuse
US7740863B2 (en) * 2001-04-06 2010-06-22 Merial Recombinant vaccine against West Nile Virus

Also Published As

Publication number Publication date
ES2424847T3 (es) 2013-10-09
EP1773387A2 (en) 2007-04-18
WO2006073431A2 (en) 2006-07-13
EP1773387A4 (en) 2008-03-19
BRPI0512421B8 (pt) 2022-06-28
EP1773387B1 (en) 2013-06-12
US20050287672A1 (en) 2005-12-29
CA2571560A1 (en) 2006-07-13
US7527960B2 (en) 2009-05-05
WO2006073431A9 (en) 2006-10-05
WO2006073431A3 (en) 2006-08-31
ECSP077196A (es) 2007-02-28
US20090253185A1 (en) 2009-10-08
CA2571560C (en) 2016-04-12
BRPI0512421B1 (pt) 2014-09-09
DK1773387T3 (da) 2013-07-15
PL1773387T3 (pl) 2013-10-31

Similar Documents

Publication Publication Date Title
BRPI0512421A (pt) recombinantes de avipox expressando genes do vìrus da doença febre aftosa
Beasley et al. Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVax™-JE experimental vaccine
TW200806316A (en) Yeast-based vaccine for inducing an immune response
WO2008054540A3 (en) Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
SG156652A1 (en) Yeast-based therapeutic for chronic hepatitis c infection
BRPI0309631A8 (pt) vacina tetravalente da dengue contendo uma trivial deleção de 30 nucleotídeos na utr-31' dos tipos de dengue 1,2,3 e 4, ou de vírus antigênicos quiméricos da dengue 1,2,3 e 4
BR112015005987A2 (pt) vacina, métodos para induzir uma resposta imune contra um antígeno hbv, para proteção de um sujeito da infeção por hbv, para proteger o sujeito que foi diagnosticado com uma infecção por hbv, para induzir uma resposta imune contra um antígeno do hbv, para proteger um indivíduo da infecção pelo hbv, para proteger um indivíduo que foi diagnosticado com infecção pelo hbv, para proteger um indivíduo da infecção pelo hbv, para proteger um indivíduo que foi diagnosticado com infecção pelo hbv, para proteger um sujeito contra infecção por hbv e para proteger o sujeito que foi diagnosticado com uma infecção por hbv, molécula de ácido nucleico, e, proteína
MX2022010588A (es) Vacuna basada en poxvirus recombinantes contra el virus sars-cov-2.
CL2012000447A1 (es) Composición o vacuna que comprende un vector viral de un paramixovirus aviar 8 (apmv-8) recombinante; método para producir dicho vector; y uso para preparar medicamento útil para inducir una respuesta inmunológica.
WO2008133208A1 (ja) ペプチド免疫応答増強方法
EP2552490A4 (en) INFLUENZA MATRIX 2 PROTEIN ECKTOMOMAS, EXPRESSION SYSTEM THEREFOR AND USES THEREOF
BR112015022582A2 (pt) molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo
MXPA05005203A (es) Vacuna contra vhc.
Wang et al. A CpG oligodeoxynucleotide acts as a potent adjuvant for inactivated rabies virus vaccine
ZA201707985B (en) Recombinant modified vaccinia virus ankara (mva) foot and mouth disease virus (fmdv) vaccine
Ballout et al. Vaccinations for adult solid organ transplant recipient: current recommendations
BRPI0904020B8 (pt) composição vacinal contra o vírus da dengue, e, kit
BRPI0416916A (pt) promotores para expressão em vìrus de vacìnia modificada ankara
Saxena et al. A sindbis virus replicon-based DNA vaccine encoding the rabies virus glycoprotein elicits immune responses and complete protection in mice from lethal challenge
WO2011084604A3 (en) Flavivirus species-specific peptide tags for vaccine and diagnostic use
TW200509964A (en) VP1 of foot-and-mouth disease virus
PT1370668E (pt) Vacinas de vector baseadas em leporipox
Kim et al. Over-passage of epithelioma papulosum cyprini (EPC) cells increased viral hemorrhagic septicemia virus (VHSV) replication
He et al. A recombinant plasmid containing CpG motifs as a novel vaccine adjuvant for immune protection against herpes simplex virus 2
BR0304750A (pt) Mutante de herpesvìrus bovino tipo 5, vacina dirigida contra a encefalite viral bovina (bhv-s) e o vìrus rábico e método de preparação da vacina

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/04/2005, OBSERVADAS AS CONDICOES LEGAIS.

B25A Requested transfer of rights approved
B25A Requested transfer of rights approved
B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 20/04/2025